Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $38.00 Average Price Target from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has been assigned a consensus rating of "Buy" from the five brokerages that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in the last year is $38.80.

Several analysts have weighed in on the stock. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective for the company. Wedbush reiterated an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Finally, Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock traded down $0.16 during trading hours on Friday, hitting $26.78. The company had a trading volume of 118,806 shares, compared to its average volume of 478,748. Kiniksa Pharmaceuticals has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The firm's fifty day moving average is $22.07 and its 200-day moving average is $21.34. The firm has a market capitalization of $1.95 billion, a P/E ratio of -191.01 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same period last year, the company posted ($0.25) earnings per share. The firm's quarterly revenue was up 72.5% compared to the same quarter last year. Analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, insider Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at approximately $191,030.35. The trade was a 65.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 224,820 shares of company stock valued at $5,386,361. 54.57% of the stock is owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several hedge funds have recently modified their holdings of KNSA. Franklin Resources Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after acquiring an additional 1,100 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Kiniksa Pharmaceuticals in the third quarter worth approximately $4,997,000. Nordea Investment Management AB raised its holdings in shares of Kiniksa Pharmaceuticals by 4.4% in the 4th quarter. Nordea Investment Management AB now owns 194,883 shares of the company's stock valued at $3,818,000 after purchasing an additional 8,257 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Kiniksa Pharmaceuticals by 1.9% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company's stock valued at $3,947,000 after acquiring an additional 3,673 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Kiniksa Pharmaceuticals during the 4th quarter worth $355,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.